Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 494372 in patients with high Lipoprotein(a)
NCT02160899Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2014
- Primary completion
- Nov 2015
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of ISIS-APO(a)Rx in elevated lipoprotein(a) (Lp(a)) (6 cohorts), sponsored by Ionis Pharmaceuticals. Primary endpoints: Percent Change From Baseline in Lipoprotein Lp(a) Plasma Concentration at Day 99 and Number of Participants With at Least One Treatment-emergent Adverse Event at 32 weeks. Started Jun 2014; status: completed.
02
Drugs
ISIS-APO(a)Rx
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT02160899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02160899.